Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 283.58B +11.4% |
| Revenue (ttm) | 92.05B +0.8% |
| Net Income | -3.14B |
| EPS | -2.36 |
| Shares Out | 1.33B |
| PE Ratio | n/a |
| Forward PE | 93.71 |
| Dividend | 0.14 (0.07%) |
| Ex-Dividend Date | Jul 16, 2025 |
| Volume | 4,572,376 |
| Open | 217.31 |
| Previous Close | 216.66 |
| Day's Range | 212.92 - 220.36 |
| 52-Week Range | 132.30 - 220.36 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 233.27 (+9.17%) |
| Earnings Date | Jul 29, 2026 |
About Piramal Pharma
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for PPLPHARMA stock is "Strong Buy." The 12-month stock price target is ₹233.27, which is an increase of 9.17% from the latest price.
News
Piramal Pharma Transcript: Q1 26/27
Q1 FY 2027 saw 17% revenue and 72% EBITDA growth, with all segments contributing and margins expanding. CDMO led with 19% growth, Complex Hospital Generics and Consumer Healthcare also performed strongly. Guidance remains unchanged, with margin expansion expected as overseas utilization improves.
Piramal Pharma Quarterly report: Q1 2027
Piramal Pharma has published its Q1 2027 quarterly earnings report on July 30, 2026.
Piramal Pharma Slides: Q1 2027
Piramal Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Piramal Pharma Transcript: Q4 25/26
FY 2026 saw modest underlying growth despite macro headwinds, with strong H2 momentum in CDMO, robust Consumer Healthcare expansion, and strategic investments positioning for early to mid-teens revenue growth in FY 2027. Net debt to EBITDA remains at 3.6x amid ongoing CapEx.
Piramal Pharma Quarterly report: Q4 2026
Piramal Pharma has published its Q4 2026 quarterly earnings report on April 29, 2026.
Piramal Pharma Slides: Q4 2026
Piramal Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 29, 2026.
Piramal Pharma Annual report: Q4 2026
Piramal Pharma has published its Q4 2026 annual report on April 29, 2026.
Piramal Pharma Transcript: Q3 25/26
Q3 FY26 saw a 3%-4% revenue decline, but early recovery signs emerged with improved US biopharma funding and order inflows. The Kenalog acquisition and ongoing capacity expansions support long-term growth, while guidance for FY27 and 2030 remains intact.
Piramal Pharma Quarterly report: Q3 2026
Piramal Pharma has published its Q3 2026 quarterly earnings report on January 28, 2026.
Piramal Pharma Slides: Q3 2026
Piramal Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 28, 2026.
Piramal Pharma Transcript: Q2 25/26
Revenue and EBITDA margins declined year-over-year due to a major CDMO customer destocking, but net debt was reduced and consumer healthcare showed strong growth. Guidance for FY 2026 was moderated to flat revenue and low teens EBITDA margin, with H2 expected to outperform H1.
Piramal Pharma Quarterly report: Q2 2026
Piramal Pharma has published its Q2 2026 quarterly earnings report on November 5, 2025.
Piramal Pharma Slides: Q2 2026
Piramal Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 5, 2025.